Patient Preference and Adherence · 2017 · 10 citations · 17 references
MedicineNeurologyClinical Decision SupportDisease PreventionOutcomes ResearchDecision-analytic ModelingMultiple SclerosisMultiple Sclerosis PharmacotherapyRelapse PreventionDisease Progression ControlEliciting Patient PreferencesGeometric Data ModelMedication Preference AssessmentMultidimensional UnfoldingMultiple Sclerosis TherapyPreference RatingRelapsing-remitting Multiple Sclerosis Treatment
PURPOSE: Multidimensional unfolding is a multivariate method to assess preferences using a small sample size, a geometric model locating individuals and alternatives as points in a joint space. The objective was to evaluate relapsing-remitting multiple sclerosis (RRMS) patient preferences toward key disease-modifying therapy (DMT) attributes using multidimensional unfolding. PATIENTS AND METHODS: A cross-sectional pilot study in RRMS patients was conducted. Drug attributes included relapse prevention, disease progression prevention, side-effect risk and route and schedule of administration. Assessment of preferences was performed through a five-card game. Patients were asked to value attributes from 1 (most preferred) to 5 (least preferred). RESULTS: A total of 37 patients were included; the mean age was 38.6 years, and 78.4% were female. Disease progression prevention was the most important factor (51.4%), followed by relapse prevention (40.5%). The frequency of administration had the lowest preference rating for 56.8% of patients. Finally, 19.6% valued the side-effect risk attribute as having low/very low importance. CONCLUSION: Patients' perspective for DMT attributes may provide valuable information to facilitate shared decision-making. Efficacy attributes were the most important drug characteristics for RRMS patients. Multidimensional unfolding seems to be a feasible approach to assess preferences in multiple sclerosis patients. Further elicitation studies using multidimensional unfolding with other stated choice methods are necessary to confirm these findings.
17
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text
Medicine, Neurology, Neuroscience +10
Alastair Compston, Alasdair Coles · The Lancet · 2008 · 4.3K citations
New Multiple Sclerosis Phenotypic Classification
Fred Lublin · European Neurology · 2014 · 4.3K citations